Xenobiotic metabolism, disposition, and regulation by receptors: From biochemical phenomenon to predictors of major toxicities

Toxicological Sciences

Volumn 120, Issue SUPPL.1, 2011, Pages

  Omiecinski, Curtis J ^a   Vanden Heuvel, John P ^a   Perdew, Gary H ^a   Peters, Jeffrey M ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

Aryl hydrocarbon receptor; Biotransformation; Constitutive androstane receptor; Cytochrome P450; Nuclear receptor; Peroxisome proliferator activated receptor; Pregnane X receptor; Xenobiotic metabolism

Indexed keywords

1,4 BIS [2 (3,5 DICHLOROPYRIDYLOXY)]BENZENE; 2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; 5ALPHA ANDROSTAN 3 ONE; 6 (4 CHLOROPHENY)IMIDAZO [2,1 B] [1,3] THIAZOLE 5 CARBALDEHYDE O (3,4 DICHLOROBENZYL)OXIME; ACYLTRANSFERASE; AROMATIC HYDROCARBON RECEPTOR; BENZO[A]PYRENE; CELL NUCLEUS RECEPTOR; CLOTRIMAZOLE; CONSTITUTIVE ANDROSTANE RECEPTOR; CYTOCHROME P450; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; INDICAN; INDIRUBIN; KYNURENIC ACID; N (2,2,2 TRIFLUOROETHYL) N [4 (2,2,2 TRIFLUORO 1 HYDROXY 1 TRIFLUOROMETHYLETHYL)PHENYL]BENZENESULFONAMIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ANTAGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHENOBARBITAL; PREGNANE X RECEPTOR; RIFAMPICIN; SULFOTRANSFERASE; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; BIOLOGICAL ACTIVITY; BIOTRANSFORMATION; CANCER GROWTH; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOTOXICITY; ENZYME METABOLISM; ENZYME REGULATION; GENE EXPRESSION; GENE INTERACTION; GENOTOXICITY; HUMAN; INFLAMMATION; LIVER CARCINOGENESIS; NONHUMAN; OXIDATION; PREDICTOR VARIABLE; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; TRANSCRIPTION REGULATION; XENOBIOTIC METABOLISM;

ANIMALS; GENOMICS; HUMANS; METABOLIC DETOXICATION, DRUG; PREDICTIVE VALUE OF TESTS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; XENOBIOTICS;

MAMMALIA;

EID: 79952074453     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfq338     Document Type: Review

References (250)

1. Alvares, A. P., Schilling, G., Levin, W., and Kuntzman, R. (1967). Studies on the induction of CO-binding pigments in liver microsomes by phenobarbital and 3-methylcholanthrene. Biochem. Biophys. Res. Commun. 29, 521-526.
2. Amri, E. Z., Bonino, F., Ailhaud, G., Abumrad, N. A., and Grimaldi, P. A. (1995). Cloning of a protein that mediates transcriptional effects of fatty acids in preadipocytes. Homology to peroxisome proliferator-activated receptors. J. Biol. Chem. 270, 2367-2371.
3. Ashby, J., Brady, A., Elcombe, C. R., Elliott, B. M., Ishmael, J., Odum, J., Tugwood, J. D., Kettle, S., and Purchase, I. F. (1994). Mechanistically-based human hazard assessment of peroxisome proliferator-induced hepatocarcino-genesis. Hum. Exp. Toxicol. 13(Suppl. 2), S1-S117.
4. Assem, M., Schuetz, E. G., Leggas, M., Sun, D., Yasuda, K., Reid, G., Zelcer, N., Adachi, M., Strom, S., and Evans, R. M. (2004). Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice. J. Biol. Chem. 279, 22250-22257.
5. Auerbach, S. S., Ramsden, R., Stoner, M. A., Verlinde, C., Hassett, C., and Omiecinski, C. J. (2003). Alternatively spliced isoforms of the human constitutive androstane receptor. Nucleic Acids Res. 31, 3194-3207.
6. Auerbach, S. S., Stoner, M. A., Su, S., and Omiecinski, C. J. (2005). Retinoid X receptor-{alpha}-dependent transactivation by a naturally occurring structural variant of human constitutive androstane receptor (NR1I3). Mol. Pharmacol. 68, 1239-1253.
7. Baba, T., Mimura, J., Nakamura, N., Harada, N., Yamamoto, M., Morohashi, K., and Fujii-Kuriyama, Y. (2005). Intrinsic function of the aryl hydrocarbon (dioxin) receptor as a key factor in female reproduction. Mol. Cell. Biol. 25, 10040-10051.
8. Baer, A. N., and Wortmann, R. L. (2007). Myotoxicity associated with lipid-lowering drugs. Curr. Opin. Rheumatol. 19, 67-73.
9. Baes, M., Gulick, T., Choi, H. S., Martinoli, M. G., Simha, D., and Moore, D. D. (1994). A new orphan member of the nuclear hormone receptor superfamily that interacts with a subset of retinoic acid response elements. Mol. Cell. Biol. 14, 1544-1551.
10. Barbier, O., Duran-Sandoval, D., Pineda-Torra, I., Kosykh, V., Fruchart, J. C., and Staels, B. (2003). Peroxisome proliferator-activated receptor alpha induces hepatic expression of the human bile acid glucuronidating UDP-glucuronosyltransferase 2B4 enzyme. J. Biol. Chem. 278, 32852-32860.
11. Barbier, O., Fontaine, C., Fruchart, J. C., and Staels, B. (2004). Genomic and non-genomic interactions of PPARalpha with xenobiotic-metabolizing enzymes. Trends Endocrinol. Metab. 15, 324-330.
12. Beck, F., Plummer, S., Senior, P. V., Byrne, S., Green, S., and Brammar, W. J. (1992). The ontogeny of peroxisome-proliferator-activated receptor gene expression in the mouse and rat. Proc. Biol. Sci. 247, 83-87.
13. Beischlag, T. V., Luis, M. J., Hollingshead, B. D., and Perdew, G. H. (2008). The aryl hydrocarbon receptor complex and the control of gene expression. Crit. Rev. Eukaryot. Gene Expr. 18, 207-250.
14. Beischlag, T. V., and Perdew, G. H. (2005). ER alpha-AHR-ARNT protein-protein interactions mediate estradiol-dependent transrepression of dioxin-inducible gene transcription. J. Biol. Chem. 280, 21607-21611.
15. Berger, J., Leibowitz, M. D., Doebber, T. W., Elbrecht, A., Zhang, B., Zhou, G., Biswas, C., Cullinan, C. A., Hayes, N. S., Li, Y., et al. (1999). Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects. J. Biol. Chem. 274, 6718-6725.
16. Biegel, L. B., Hurtt, M. E., Frame, S. R., O'Connor, J. C., and Cook, J. C. (2001). Mechanisms of extrahepatic tumor induction by peroxisome proliferators in male CD rats. Toxicol. Sci. 60, 44-55.
17. Bility, M. T., Thompson, J. T., McKee, R. H., David, R. M., Butala, J. H., Vanden Heuvel, J. P., and Peters, J. M. (2004). Activation of mouse and human peroxisome proliferator-activated receptors (PPARs) by phthalate monoesters. Toxicol. Sci. 82, 170-182.
18. Billin, A. N. (2008). PPAR-beta/delta agonists for Type 2 diabetes and dyslipidemia: an adopted orphan still looking for a home. Expert Opin. Investig. Drugs 17, 1465-1471.
19. Birnbaum, L. S., and Tuomisto, J. (2000). Non-carcinogenic effects of TCDD in animals. Food Addit. Contam. 17, 275-288.
20. Blumberg, B., Sabbagh, W., Jr., Juguilon, H., Bolado, J., Jr., van Meter, C. M., Ong, E. S., and Evans, R. M. (1998). SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev. 12, 3195-3205.
21. Boyer, T. D. (1989). The glutathione S-transferases: an update. Hepatology 9, 486-496.
22. Braissant, O., Foufelle, F., Scotto, C., Dauca, M., and Wahli, W. (1996). Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 137, 354-366.
23. Braissant, O., and Wahli, W. (1998). Differential expression of peroxisome proliferator-activated receptor-alpha, -beta, and -gamma during rat embryonic development. Endocrinology 139, 2748-2754.
24. Bui, L. C., Tomkiewicz, C., Chevallier, A., Pierre, S., Bats, A. S., Mota, S., Raingeaud, J., Pierre, J., Diry, M., Transy, C., et al. (2009). Nedd9/Hef1/Cas-L mediates the effects of environmental pollutants on cell migration and plasticity. Oncogene 28, 3642-3651.
25. Bunger, M. K., Glover, E., Moran, S. M., Walisser, J. A., Lahvis, G. P., Hsu, E. L., and Bradfield, C. A. (2008). Abnormal liver development and resistance to 2,3,7,8-tetrachlorodibenzo-p-dioxin toxicity in mice carrying a mutation in the DNA-binding domain of the aryl hydrocarbon receptor. Toxicol. Sci. 106, 83-92.
26. Bunger, M. K., Moran, S. M., Glover, E., Thomae, T. L., Lahvis, G. P., Lin, B. C., and Bradfield, C. A. (2003). Resistance to 2,3,7,8-tetrachlorodibenzo-p-dioxin toxicity and abnormal liver development in mice carrying a mutation in the nuclear localization sequence of the aryl hydrocarbon receptor. J. Biol. Chem. 278, 17767-17774.
27. Burdick, A. D., Bility, M. T., Girroir, E. E., Billin, A. N., Willson, T. M., Gonzalez, F. J., and Peters, J. M. (2007). Ligand activation of peroxisome proliferator-activated receptor-beta/delta(PPARbeta/delta) inhibits cell growth of human N/TERT-1 keratinocytes. Cell. Signal. 19, 1163-1171.
28. Burdick, A. D., Kim, D. J., Peraza, M. A., Gonzalez, F. J., and Peters, J. M. (2006). The role of peroxisome proliferator-activated receptor-beta/delta in epithelial cell growth and differentiation. Cell Signal. 18, 9-20.
29. Burk, O., Arnold, K. A., Nussler, A. K., Schaeffeler, E., Efimova, E., Avery, B. A., Avery, M. A., Fromm, M. F., and Eichelbaum, M. (2005). Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. Mol. Pharmacol. 67, 1954-1965.
30. Caldwell, J. A. (1986). Xenobiotic metabolism: mammalian aspects. ACS Symp. Ser. Am. Chem. Soc. 299, 2-28.
31. Carvajal-Gonzalez, J. M., Mulero-Navarro, S., Roman, A. C., Sauzeau, V., Merino,J.M., Bustelo, X.R., and Fernandez-Salguero, P. M.(2009). The dioxin receptor regulates the constitutive expression of the vav3 proto-oncogene and modulates cell shape and adhesion. Mol. Biol. Cell 20, 1715-1727.
32. Chambon, P. (2005). The nuclear receptor superfamily: a personal retrospect on the first two decades. Mol. Endocrinol. 19, 1418-1428.
33. Chang, T. K., and Waxman, D. J. (2006). Synthetic drugs and natural products as modulators of constitutive androstane receptor (CAR) and pregnane X receptor (PXR). Drug Metab. Rev. 38, 51-73.
34. Cheng, N., He, R., Tian, J., Ye, P. P., and Ye, R. D. (2008). Cutting edge: TLR2 is a functional receptor for acute-phase serum amyloid A. J. Immunol. 181, 22-26.
35. Cheung, C., Akiyama, T. E., Ward, J. M., Nicol, C. J., Feigenbaum, L., Vinson, C., and Gonzalez, F. J. (2004). Diminished hepatocellular proliferation in mice humanized for the nuclear receptor peroxisome proliferator-activated receptor alpha. Cancer Res. 64, 3849-3854.
36. Chintharlapalli, S., Papineni, S., Konopleva, M., Andreef, M., Samudio, I., and Safe, S. (2005). 2-Cyano-3,12-dioxoolean-1,9-dien-28-oic acid and related compounds inhibit growth of colon cancer cells through peroxisome proliferator-activated receptor gamma-dependent and -independent pathways. Mol. Pharmacol. 68, 119-128.
37. Chintharlapalli, S., Papineni, S., Liu, S., Jutooru, I., Chadalapaka, G., Cho, S. D., Murthy, R. S., You, Y., and Safe, S. (2007). 2-Cyano-lup-1-en-3-oxo-20-oic acid, a cyano derivative of betulinic acid, activates peroxisome proliferator-activated receptor gamma in colon and pancreatic cancer cells. Carcinogenesis 28, 2337-2346.
38. Choi, H. S., Chung, M., Tzameli, I., Simha, D., Lee, Y. K., Seol, W., and Moore, D. D. (1997). Differential transactivation by two isoforms of the orphan nuclear hormone receptor CAR. J. Biol. Chem. 272, 23565-23571.
39. Chojkier, M. (2005). Troglitazone and liver injury: in search of answers. Hepatology 41, 237-246.
40. Conney, A. H., Miller, E. C., and Miller, J. A. (1956). The metabolism of methylated aminoazo dyes. V. Evidence for induction of enzyme synthesis in the rat by 3-methylcholanthrene. Cancer Res. 16, 450-459.
41. Dean, M., and Annilo, T. (2005). Evolution of the ATP-binding cassette (ABC) transporter superfamily in vertebrates. Annu. Rev. Genomics Hum. Genet. 6, 123-142.
42. Degner, S. C., Kemp, M. Q., Hockings, J. K., and Romagnolo, D. F. (2007). Cyclooxygenase-2 promoter activation by the aromatic hydrocarbon receptor in breast cancer mcf-7 cells: repressive effects of conjugated linoleic acid. Nutr. Cancer 59, 248-257.
43. Dekeyser, J. G., and Omiecinski, C. J. (2010). Constitutive androstane receptor. In Comprehensive Toxicology: Vol. 2-Cellular and Molecular Toxicology, 2nd ed. (C. A. McQueen, Ed.), pp. 169-181. Elsevier, New York, NY.
44. Dekeyser, J. G., Stagliano, M. C., Auerbach, S. S., Prabu, K. S., Jones, A. D., and Omiecinski, C. J. (2009). Di(2-ethylhexyl) phthalate is a highly potent agonist for the human constitutive androstane receptor splice variant, CAR2. Mol. Pharmacol. 75, 1005-1013.
45. Denison, M. S., and Nagy, S. R. (2003). Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu. Rev. Pharmacol. Toxicol. 43, 309-334.
46. Di-Poi, N., Tan, N. S., Michalik, L., Wahli, W., and Desvergne, B. (2002). Antiapoptotic role of PPARbeta in keratinocytes via transcriptional control of the Akt1 signaling pathway. Mol. Cell 10, 721-733.
47. DiNatale, B. C., Murray, I. A., Schroeder, J. C., Flaveny, C. A., Lahoti, T. S., Laurenzana, E. M., Omiecinski, C. J., and Perdew, G. H. (2010a). Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling. Toxicol. Sci. 115, 89-97.
48. DiNatale, B. C., Schroeder, J. C., Francey, L. J., Kusnadi, A., and Perdew, G. H. (2010b). Mechanistic insights into the events that lead to synergistic induction of interleukin 6 transcription upon activation of the aryl hydrocarbon receptor and inflammatory signaling. J. Biol. Chem. 285, 24388-24397.
49. Dong, B., Saha, P. K., Huang, W., Chen, W., Abu-Elheiga, L. A., Wakil, S. J., Stevens, R. D., Ilkayeva, O., Newgard, C. B., Chan, L., et al. (2009). Activation of nuclear receptor CAR ameliorates diabetes and fatty liver disease. Proc. Natl. Acad. Sci. U.S.A. 106, 18831-18836.
50. Dreyer, C., Krey, G., Keller, H., Givel, F., Helftenbein, G., and Wahli, W. (1992). Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell 68, 879-887.
51. Ebert, B., Seidel, A., and Lampen, A. (2005). Identification of BCRP as transporter of benzo[a]pyrene conjugates metabolically formed in Caco-2 cells and its induction by Ah-receptor agonists. Carcinogenesis 26, 1754-1763.
52. Eloranta, J. J., Meier, P. J., and Kullak-Ublick, G. A. (2005). Coordinate transcriptional regulation of transport and metabolism. Methods Enzymol. 400, 511-530.
53. Ema, M., Ohe, N., Suzuki, M., Mimura, J., Sogawa, K., Ikawa, S., and Fujii-Kuriyama, Y. (1994). Dioxin binding activities of polymorphic forms of mouse and human arylhydrocarbon receptors. J. Biol. Chem. 269, 27337-27343.
54. Escher, P., Braissant, O., Basu-Modak, S., Michalik, L., Wahli, W., and Desvergne, B. (2001). Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology 142, 4195-4202.
55. Faiola, B., Falls, J. G., Peterson, R. A., Bordelon, N. R., Brodie, T. A., Cummings, C. A., Romach, E. H., and Miller, R. T. (2008). PPAR alpha, more than PPAR delta, mediates the hepatic and skeletal muscle alterations induced by the PPAR agonist GW0742. Toxicol. Sci. 105, 384-394.
56. Fajas, L., Auboeuf, D., Raspe, E., Schoonjans, K., Lefebvre, A. M., Saladin, R., Najib, J., Laville, M., Fruchart, J. C., Deeb, S., et al. (1997). The organization, promoter analysis, and expression of the human PPARgamma gene. J. Biol. Chem. 272, 18779-18789.
57. Fajas, L., Fruchart, J. C., and Auwerx, J. (1998). PPARgamma3 mRNA: a distinct PPARgamma mRNA subtype transcribed from an independent promoter. FEBS Lett. 438, 55-60.
58. Fang, H. L., Strom, S. C., Cai, H., Falany, C. N., Kocarek, T. A., and Runge-Morris, M. (2005). Regulation of human hepatic hydroxy-steroid sulfotransferase gene expression by the peroxisome proliferator-activated receptor alpha transcription factor. Mol. Pharmacol. 67, 1257-1267.
59. Faucette, S. R., Zhang, T. C., Moore, R., Sueyoshi, T., Omiecinski, C. J., LeCluyse, E. L., Negishi, M., and Wang, H. (2007). Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J. Pharmacol. Exp. Ther. 320, 72-80.
60. Ferko, A., Bedma, J., and Nozicka, J. (2003). Pigmented hepatocellular adenoma of the liver caused by long-term use of phenobarbital. Rozhl. Chir. 82, 192-195.
61. Flaveny, C. A., Murray, I. A., Chiaro, C. R., and Perdew, G. H. (2009). Ligand selectivity and gene regulation by the human aryl hydrocarbon receptor in transgenic mice. Mol. Pharmacol. 75, 1412-1420.
62. Foreman, J. E., Sorg, J. M., McGinnis, K. S., Rigas, B., Williams, J. L., Clapper, M. L., Gonzalez, F. J., and Peters, J. M. (2009). Regulation of peroxisome proliferator-activated receptor-beta/delta by the APC/beta-CATENIN pathway and nonsteroidal antiinflammatory drugs. Mol. Carcinog. 48, 942-952.
63. Forman, B. M., Chen, J., and Evans, R. M. (1997). Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc. Natl. Acad. Sci. U.S.A. 94, 4312-4317.
64. Fritz, W. A., Lin, T. M., Safe, S., Moore, R. W., and Peterson, R. E. (2009). The selective aryl hydrocarbon receptor modulator 6-methyl-1,3, 8-trichlorodibenzofuran inhibits prostate tumor metastasis in TRAMP mice. Biochem. Pharmacol. 77, 1151-1160.
65. Fujiwara, T., Yoshioka, S., Yoshioka, T., Ushiyama, I., and Horikoshi, H. (1988). Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 37, 1549-1558.
66. Fukumoto, K., Yano, Y., Virgona, N., Hagiwara, H., Sato, H., Senba, H., Suzuki, K., Asano, R., Yamada, K., and Yano, T. (2005). Peroxisome proliferator-activated receptor delta as a molecular target to regulate lung cancer cell growth. FEBS Lett. 579, 3829-3836.
67. Gabay, C., and Kushner, I. (1999). Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med. 340, 448-454.
68. Gao, J., He, J., Zhai, Y., Wada, T., and Xie, W. (2009). The constitutive androstane receptor is an anti-obesity nuclear receptor that improves insulin sensitivity. J. Biol. Chem. 284, 25984-25992.
69. Gao, J., and Xie, W. (2010). PXR and CAR at the crossroad of drug metabolism and energy metabolism. Drug Metab. Dispos. 38, 2091-2095.
70. Gasiewicz, T. A., Henry, E. C., and Collins, L. L. (2008). Expression and activity of aryl hydrocarbon receptors in development and cancer. Crit. Rev. Eukaryot. Gene Expr. 18, 279-321.
71. Gillmore, J. D., Lovat, L. B., Persey, M. R., Pepys, M. B., and Hawkins, P. N. (2001). Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 358, 24-29.
72. Gillner, M., Bergman, J., Cambillau, C., Alexandersson, M., Fernstrom, B., and Gustafsson, J. A. (1993). Interactions of indolo[3,2-b]carbazoles and related polycyclic aromatic hydrocarbons with specific binding sites for 2,3,7,8-tetrachlorodibenzo-p-dioxin in rat liver. Mol. Pharmacol. 44, 336-345.
73. Girroir, E. E., Hollingshead, H. E., He, P., Zhu, B., Perdew, G. H., and Peters, J. M. (2008). Quantitative expression patterns of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) protein in mice. Biochem. Biophys. Res. Commun. 371, 456-461.
74. Glass, C. K., and Rosenfeld, M. G. (2000). The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev. 14, 121-141.
75. Glass, C. K., and Saijo, K. (2010). Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells. Nat. Rev. Immunol. 10, 365-376.
76. Gonzalez, F. J., and Shah, Y. M. (2008). PPARalpha: mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators. Toxicology 246, 2-8.
77. Guan, Y., Hao, C., Cha, D. R., Rao, R., Lu, W., Kohan, D. E., Magnuson, M. A., Redha, R., Zhang, Y., and Breyer, M. D. (2005). Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat. Med. 11, 861-866.
78. Guengerich, F. P., Dannan, G. A., Wright, S. T., Martin, M. V., and Kaminsky, L. S. (1982). Purification and characterization of liver microsomal cytochromes p-450: electrophoretic, spectral, catalytic, and immunochemical properties and inducibility of eight isozymes isolated from rats treated with phenobarbital or beta-naphthoflavone. Biochemistry 21, 6019-6030.
79. Guo, J., Chintharlapalli, S., Lee, S. O., Cho, S. D., Lei, P., Papineni, S., and Safe, S. (2010). Peroxisome proliferator-activated receptor gamma-dependent activity of indole ring-substituted 1,1-bis(3'-indolyl)-1-(p-biphenyl) methanes in cancer cells. Cancer Chemother. Pharmacol. 66, 141-150.
80. Gupta, R. A., Tan, J., Krause, W. F., Geraci, M. W., Willson, T. M., Dey, S. K., and DuBois, R. N. (2000). Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc. Natl. Acad. Sci. U.S.A. 97, 13275-13280.
81. Hagenbuch, B. (2010). Drug uptake systems in liver and kidney: a historic perspective. Clin. Pharmacol. Ther. 87, 39-47.
82. Han, S., Ritzenthaler, J. D., Zheng, Y., and Roman, J. (2008). PPARbeta/delta agonist stimulates human lung carcinoma cell growth through inhibition of PTEN expression: the involvement of PI3K and NF-kappaB signals. Am. J. Physiol. Lung Cell. Mol. Physiol. 294, L1238-L1249.
83. Handschin, C., Lin, J., Rhee, J., Peyer, A. K., Chin, S., Wu, P. H., Meyer, U. A., and Spiegelman, B. M. (2005). Nutritional regulation of hepatic heme biosynthesis and porphyria through PGC-1alpha. Cell 122, 505-515.
84. Handschin, C., and Meyer, U. A. (2005). Regulatory network of lipid-sensing nuclear receptors: roles for CAR, PXR, LXR, and FXR. Arch. Biochem. Biophys. 433, 387-396.
85. Hankinson, O. (1995). The aryl hydrocarbon receptor complex. Annu. Rev. Pharmacol. Toxicol. 35, 307-340.
86. Harper, P. A., Golas, C. L., and Okey, A. B. (1988). Characterization of the Ah receptor and aryl hydrocarbon hydroxylase induction by 2,3,7, 8-tetrachlorodibenzo-p-dioxin and benz(a)anthracene in the human A431 squamous cell carcinoma line. Cancer Res. 48, 2388-2395.
87. Hashimoto, Y., Loftis, D. W., and Adams, J. C. (2009). Fascin-1 promoter activity is regulated by CREB and the aryl hydrocarbon receptor in human carcinoma cells. PLoS ONE 4, e5130.
88. He, P., Borland, M. G., Zhu, B., Sharma, A. K., Amin, S., El-Bayoumy, K., Gonzalez, F. J., and Peters, J. M. (2008). Effect of ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) in human lung cancer cell lines. Toxicology 254, 112-117.
89. Hess, R., Staubli, W., and Riess, W. (1965). Nature of the hepatomegalic effect produced by ethyl-chlorophenoxy-isobutyrate in the rat. Nature 208, 856-858.
90. Hollingshead, H. E., Killins, R. L., Borland, M. G., Girroir, E. E., Billin, A. N., Willson, T. M., Sharma, A. K., Amin, S., Gonzalez, F. J., and Peters, J. M. (2007). Peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) ligands do not potentiate growth of human cancer cell lines. Carcinogenesis 28, 2641-2649.
91. Holsapple, M. P., Pitot, H. C., Cohen, S. M., Boobis, A. R., Klaunig, J. E., Pastoor, T., Dellarco, V. L., and Dragan, Y. P. (2006). Mode of action in relevance of rodent liver tumors to human cancer risk. Toxicol. Sci. 89, 51-56.
92. Honkakoski, P., and Negishi, M. (1997). Characterization of a phenobarbital-responsive enhancer module in mouse P450 Cyp2b10 gene. J. Biol. Chem. 272, 14943-14949.
93. Huang, W., Zhang, J., and Moore, D. D. (2004a). A traditional herbal medicine enhances bilirubin clearance by activating the nuclear receptor CAR. J. Clin. Invest. 113, 137-143.
94. Huang, W., Zhang, J., Washington, M., Liu, J., Parant, J. M., Lozano, G., and Moore, D. D. (2005). Xenobiotic stress induces hepatomegaly and liver tumors via the nuclear receptor constitutive androstane receptor. Mol. Endocrinol. 19, 1646-1653.
95. Huang, W., Zhang, J., Wei, P., Schrader, W. T., and Moore, D. D. (2004b). Meclizine is an agonist ligand for mouse constitutive androstane receptor (CAR) and an inverse agonist for human CAR. Mol. Endocrinol. 18, 2402-2408.
96. IJpenberg, A., Jeannin, E., Wahli, W., and Desvergne, B. (1997). Polarity and specific sequence requirements of peroxisome proliferator-activated receptor (PPAR)/retinoid X receptor heterodimer binding to DNA. A functional analysis of the malic enzyme gene PPAR response element. J. Biol. Chem. 272, 20108-20117.
97. Ikuta, T., and Kawajiri, K. (2006). Zinc finger transcription factor Slug is a novel target gene of aryl hydrocarbon receptor. Exp. Cell Res. 312, 3585-3594.
98. Ishida, M., Mikami, S., Kikuchi, E., Kosaka, T., Miyajima, A., Nakagawa, K., Mukai, M., Okada, Y., and Oya, M. (2010). Activation of the aryl hydrocarbon receptor pathway enhances cancer cell invasion by upregulating the MMP expression and is associated with poor prognosis in upper urinary tract urothelial cancer. Carcinogenesis 31, 287-295.
99. Issemann, I., and Green, S. (1990). Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347, 645-650.
100. Jensen, B. A., Leeman, R. J., Schlezinger, J. J., and Sherr, D. H. (2003). Aryl hydrocarbon receptor (AhR) agonists suppress interleukin-6 expression bybone marrow stromal cells: an immunotoxicology study. Environ. Health 2, 16.
101. Juge-Aubry, C., Pernin, A., Favez, T., Burger, A. G., Wahli, W., Meier, C. A., and Desvergne, B. (1997). DNA binding properties of peroxisome proliferator-activated receptor subtypes on various natural peroxisome proliferator response elements. Importance of the 5'-flanking region. J. Biol. Chem. 272, 25252-25259.
102. Juliano, R. L., and Ling, V. (1976). A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 455, 152-162.
103. Kast, H. R., Goodwin, B., Tarr, P. T., Jones, S. A., Anisfeld, A. M., Stoltz, C. M., Tontonoz, P., Kliewer, S., Willson, T. M., and Edwards, P. A. (2002). Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J. Biol. Chem. 277, 2908-2915.
104. Keller, H., Dreyer, C., Medin, J., Mahfoudi, A., Ozato, K., and Wahli, W. (1993). Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor hetero-dimers. Proc. Natl. Acad. Sci. U.S.A. 90, 2160-2164.
105. Kilgore, K. S., and Billin, A. N. (2008). PPARbeta/delta ligands as modulators of the inflammatory response. Curr. Opin. Investig. Drugs 9, 463-469.
106. Kim, D. J., Bility, M. T., Billin, A. N., Willson, T. M., Gonzalez, F. J., and Peters, J. M. (2006). PPARbeta/delta selectively induces differentiation and inhibits cell proliferation. Cell Death. Differ. 13, 53-60.
107. Kimura, A., Naka, T., Nohara, K., Fujii-Kuriyama, Y., and Kishimoto, T. (2008). Aryl hydrocarbon receptor regulates Stat1 activation and participates in the development of Th17 cells. Proc. Natl. Acad. Sci. U.S.A. 105, 9721-9726.
108. Kitamura, M., and Kasai, A. (2007). Cigarette smoke as a trigger for the dioxin receptor-mediated signaling pathway. Cancer Lett. 252, 184-194.
109. Klaunig, J. E., Babich, M. A., Baetcke, K. P., Cook, J. C., Corton, J. C., David, R. M., DeLuca, J. G., Lai, D. Y., McKee, R. H., Peters, J. M., et al. (2003). PPARalpha agonist-induced rodent tumors: modes of action and human relevance. Crit. Rev. Toxicol. 33, 655-780.
110. Kliewer, S. A., Forman, B. M., Blumberg, B., Ong, E. S., Borgmeyer, U., Mangelsdorf, D. J., Umesono, K., and Evans, R. M. (1994). Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc. Natl. Acad. Sci. U.S.A. 91, 7355-7359.
111. Kliewer, S. A., Moore, J. T., Wade, L., Staudinger, J. L., Watson, M. A., Jones, S. A., McKee, D. D., Oliver, B. B., Willson, T. M., Zetterstrom, R. H., et al. (1998). An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 92, 73-82.
112. Kliewer, S. A., Sundseth, S. S., Jones, S. A., Brown, P. J., Wisely, G. B., Koble, C. S., Devchand, P., Wahli, W., Willson, T. M., and Lenhard, J. M. (1997). Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc. Natl. Acad. Sci. U.S.A. 94, 4318-4323.
113. Klingenberg, M. (1958). Pigments of rat liver microsomes. Arch. Biochem. Biophys. 75, 376-386.
114. Knerr, S., and Schrenk, D. (2006). Carcinogenicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin in experimental models. Mol. Nutr. Food Res. 50, 897-907.
115. Kodama, S., Koike, C., Negishi, M., and Yamamoto, Y. (2004). Nuclear receptors CAR and PXR cross talk with FOXO1 to regulate genes that encode drug-metabolizing and gluconeogenic enzymes. Mol. Cell. Biol. 24, 7931-7940.
116. Kodama, S., and Negishi, M. (2006). Phenobarbital confers its diverse effects by activating the orphan nuclear receptor car. Drug Metab. Rev. 38, 75-87.
117. Kohle, C., and Bock, K. W. (2009). Coordinate regulation of human drug-metabolizing enzymes, and conjugate transporters by the Ah receptor, pregnane X receptor and constitutive androstane receptor. Biochem. Pharmacol. 77, 689-699.
118. Konno, Y., Negishi, M., and Kodama, S. (2008). The roles of nuclear receptors CAR and PXR in hepatic energy metabolism. Drug Metab. Pharmacokinet. 23, 8-13.
119. Korzeniewski, N., Wheeler, S., Chatterjee, P., Duensing, A., and Duensing, S. (2010). A novel role of the aryl hydrocarbon receptor (AhR) in centrosome amplification-implications for chemoprevention. Mol. Cancer 9, 153.
120. Krey, G., Braissant, O., L'Horset, F., Kalkhoven, E., Perroud, M., Parker, M. G., and Wahli, W. (1997). Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol. Endocrinol. 11, 779-791.
121. Kumar, M. B., and Perdew, G. H. (1999). Nuclear receptor coactivator SRC-1 interacts with the Q-rich subdomain of the AHR and modulates its transactivation potential. Gene Expr. 8, 273-286.
122. Kumar, R., and Thompson, E. B. (1999). The structure of the nuclear hormone receptors. Steroids 64, 310-319.
123. Kurokawa, Y., Takamura, N., Matushima, Y., Imazawa, T., and Hayashi, Y. (1988). Promoting effect of peroxisome proliferators in two-stage rat renal tumorigenesis. Cancer Lett. 43, 145-149.
124. Lahtela, J. T., Arranto, A. J., and Sotaniemi, E. A. (1985). Enzyme inducers improve insulin sensitivity in non-insulin-dependent diabetic subjects. Diabetes 34, 911-916.
125. Lahvis, G. P., Pyzalski, R. W., Glover, E., Pitot, H. C., McElwee, M. K., and Bradfield, C. A. (2005). The aryl hydrocarbon receptor is required for developmental closure of the ductus venosus in the neonatal mouse. Mol. Pharmacol. 67, 714-720.
126. Lamminpaa, A., Pukkala, E., Teppo, L., and Neuvonen, P. J. (2002). Cancer incidence among patients using antiepileptic drugs: a long-term follow-up of 28,000 patients. Eur. J. Clin. Pharmacol. 58, 137-141.
127. Lee, C. H., Olson, P., Hevener, A., Mehl, I., Chong, L. W., Olefsky, J. M., Gonzalez, F. J., Ham, J., Kang, H., Peters, J. M., et al. (2006a). PPARdelta regulates glucose metabolism and insulin sensitivity. Proc. Natl. Acad. Sci. U.S.A. 103, 3444-3449.
128. Lee, M. S., Yoo, S. A., Cho, C. S., Suh, P. G., Kim, W. U., and Ryu, S. H. (2006b). Serum amyloid A binding to formyl peptide receptor-like 1 induces synovial hyperplasia and angiogenesis. J. Immunol. 177, 5585-5594.
129. Lee, S. S., Pineau, T., Drago, J., Lee, E. J., Owens, J. W., Kroetz, D. L., Fernandez-Salguero, P. M., Westphal, H., and Gonzalez, F. J. (1995). Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol. Cell. Biol. 15, 3012-3022.
130. Lee, W. M. (2003). Acute liver failure in the United States. Semin. Liver Dis. 23, 217-226.
131. Lehmann, J. M., McKee, D. D., Watson, M. A., Willson, T. M., Moore, J. T., and Kliewer, S. A. (1998). The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J. Clin. Invest. 102, 1016-1023.
132. Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., and Kliewer, S. A. (1995). An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem. 270, 12953-12956.
133. Lu, A. Y., and Coon, M. J. (1968). Role of hemoprotein P-450 in fatty acid omega-hydroxylation in a soluble enzyme system from liver microsomes. J. Biol. Chem. 243, 1331-1332.
134. Lu, Y. F., Santostefano, M., Cunningham, B. D., Threadgill, M. D., and Safe, S. (1996). Substituted flavones as aryl hydrocarbon (Ah) receptor agonists and antagonists. Biochem. Pharmacol. 51, 1077-1087.
135. Luci, S., Giemsa, B., Kluge, H., and Eder, K. (2007). Clofibrate causes an upregulation of PPAR-{alpha} target genes but does not alter expression of SREBP target genes in liver and adipose tissue of pigs. Am. J. Physiol. Regul. Integr. Comp. Physiol. 293, R70-R77.
136. Lund, A. K., Agbor, L. N., Zhang, N., Baker, A., Zhao, H., Fink, G. D., Kanagy, N. L., and Walker, M. K. (2008). Loss of the aryl hydrocarbon receptor induces hypoxemia, endothelin-1, and systemic hypertension at modest altitude. Hypertension 51, 803-809.
137. Ma, Q., and Lu, A. Y. (2007). CYP1A induction and human risk assessment: an evolving tale of in vitro and in vivo studies. Drug Metab. Dispos. 35, 1009-1016.
138. Maglich, J. M., Parks, D. J., Moore, L. B., Collins, J. L., Goodwin, B., Billin, A. N., Stoltz, C. A., Kliewer, S. A., Lambert, M. H., Willson, T. M., et al. (2003). Identification of a novel human constitutive androstane receptor (CAR) agonist and its use in the identification of CAR target genes. J. Biol. Chem. 278, 17277-17283.
139. Maglich, J. M., Stoltz, C. M., Goodwin, B., Hawkins-Brown, D., Moore, J. T., and Kliewer, S. A. (2002). Nuclear pregnane x receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Mol. Pharmacol. 62, 638-646.
140. Maglich, J. M., Watson, J., McMillen, P. J., Goodwin, B., Willson, T. M., and Moore, J. T. (2004). The nuclear receptor CAR is a regulator of thyroid hormone metabolism during caloric restriction. J. Biol. Chem. 279, 19832-19838.
141. Malle, E., Sodin-Semrl, S., and Kovacevic, A. (2009). Serum amyloid A: an acute-phase protein involved in tumour pathogenesis. Cell. Mol. Life Sci. 66, 9-26.
142. Mangelsdorf, D. J., and Evans, R. M. (1995). The RXR heterodimers and orphan receptors. Cell 83, 841-850.
143. Marin, H. E., Peraza, M. A., Billin, A. N., Willson, T. M., Ward, J. M., Kennett, M. J., Gonzalez, F. J., and Peters, J. M. (2006). Ligand activation of peroxisome proliferator-activated receptor beta inhibits colon carcinogenesis. Cancer Res. 66, 4394-4401.
144. Marsman, D. S., and Popp, J. A. (1994). Biological potential of basophilic hepatocellular foci and hepatic adenoma induced by the peroxisome proliferator, Wy-14,643. Carcinogenesis 15, 111-117.
145. Matsuo, H., and Strauss, J. F., III. (1994). Peroxisome proliferators and retinoids affect JEG-3 choriocarcinoma cell function. Endocrinology 135, 1135-1145.
146. McMillan, B. J., and Bradfield, C. A. (2007). The aryl hydrocarbon receptor sans xenobiotics: endogenous function in genetic model systems. Mol. Pharmacol. 72, 487-498.
147. Michalik, L., Desvergne, B., and Wahli, W. (2004). Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat. Rev. Cancer 4, 61-70.
148. Mitro, N., Vargas, L., Romeo, R., Koder, A., and Saez, E. (2007). T0901317 is a potent PXR ligand: implications for the biology ascribed to LXR. FEBS Lett. 581, 1721-1726.
149. Moennikes, O., Buchmann, A., Ott, T., Willecke1, K., and Schwarz, M. (1999). The effect of connexin32 null mutation on hepatocarcinogenesis in different mouse strains. Carcinogenesis 20, 1379-1382.
150. Moennikes, O., Buchmann, A., Romualdi, A., Ott, T., Werringloer, J., Willecke, K., and Schwarz, M. (2000). Lack of phenobarbital-mediated promotion of hepatocarcinogenesis in connexin32-null mice. Cancer Res. 60, 5087-5091.
151. Moore, D. D., Kato, S., Xie, W., Mangelsdorf, D. J., Schmidt, D. R., Xiao, R., and Kliewer, S. A. (2006). International Union of Pharmacology. LXII. The NR1H and NR1I receptors: constitutive androstane receptor, pregnene X receptor, farnesoid X receptor alpha, farnesoid X receptor beta, liver X receptor alpha, liver X receptor beta, and vitamin D receptor. Pharmacol. Rev. 58, 742-759.
152. Moore, J. T., and Kliewer, S. A. (2000). Use of the nuclear receptor PXR to predict drug interactions. Toxicology 153, 1-10.
153. Moore, L. B., Goodwin, B., Jones, S. A., Wisely, G. B., Serabjit-Singh, C. J., Willson, T. M., Collins, J. L., and Kliewer, S. A. (2000a). St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc. Natl. Acad. Sci. U.S.A. 97, 7500-7502.
154. Moore, L. B., Parks, D. J., Jones, S. A., Bledsoe, R. K., Consler, T. G., Stimmel, J. B., Goodwin, B., Liddle, C., Blanchard, S. G., Willson, T. M., et al. (2000b). Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. J. Biol. Chem. 275, 15122-15127.
155. Morales, J. L., Krzeminski, J., Amin, S., and Perdew, G. H. (2008). Characterization of the antiallergic drugs 3-[2-(2-phenylethyl) benzoimidazole-4-yl]-3-hydroxypropanoic acid and ethyl 3-hydroxy-3-[2-(2-phenylethyl) benzoimidazol-4-yl]propanoate as full aryl hydrocarbon receptor agonists. Chem. Res. Toxicol. 21, 472-482.
156. Moreau, A., Vilarem, M. J., Maurel, P., and Pascussi, J. M. (2008). Xenoreceptors CAR and PXR activation and consequences on lipid metabolism, glucose homeostasis, and inflammatory response. Mol. Pharm. 5, 35-41.
157. Morimura, K., Cheung, C., Ward, J. M., Reddy, J. K., and Gonzalez, F. J. (2006). Differential susceptibility of mice humanized for peroxisome proliferator-activated receptor alpha to Wy-14,643-induced liver tumorigen-esis. Carcinogenesis 27, 1074-1080.
158. Muller, A. J., Sharma, M. D., Chandler, P. R., Duhadaway, J. B., Everhart, M. E., Johnson, B. A., III., Kahler, D. J., Pihkala, J., Soler, A. P., Munn, D. H., et al. (2008). Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proc. Natl. Acad. Sci. U.S.A. 105, 17073-17078.
159. Murray, I. A., Krishnegowda, G., DiNatale, B. C., Flaveny, C., Chiaro, C., Lin, J. M., Sharma, A. K., Amin, S., and Perdew, G. H. (2010a). Development of a selective modulator of aryl hydrocarbon (Ah) receptor activity that exhibits anti-inflammatory properties. Chem. Res. Toxicol. 23, 955-966.
160. Murray, I. A., Morales, J. L., Flaveny, C. A., DiNatale, B. C., Chiaro, C., Gowdahalli, K., Amin, S., and Perdew, G. H. (2010b). Evidence for ligand-mediated selective modulation of aryl hydrocarbon receptor activity. Mol. Pharmacol. 77, 247-254.
161. Murray, I. A., Reen, R. K., Leathery, N., Ramadoss, P., Bonati, L., Gonzalez, F. J., Peters, J. M., and Perdew, G. H. (2005). Evidence that ligand binding is a key determinant of Ah receptor-mediated transcriptional activity. Arch. Biochem. Biophys. 442, 59-71.
162. Mutoh, S., Osabe, M., Inoue, K., Moore, R., Pedersen, L., Perera, L., Rebolloso, Y., Sueyoshi, T., and Negishi, M. (2009). Dephosphorylation of threonine 38 is required for nuclear translocation and activation of human xenobiotic receptor CAR (NR1I3). J. Biol. Chem. 284, 34785-34792.
163. Nagasawa, T., Inada, Y., Nakano, S., Tamura, T., Takahashi, T., Maruyama, K., Yamazaki, Y., Kuroda, J., and Shibata, N. (2006). Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. Eur. J. Pharmacol. 536, 182-191.
164. Nagy, L., Tontonoz, P., Alvarez, J. G., Chen, H., and Evans, R. M. (1998). Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 93, 229-240.
165. Naruhn, S., Meissner, W., Adhikary, T., Kaddatz, K., Klein, T., Watzer, B., Muller-Brusselbach, S., and Muller, R. (2010). 15-Hydroxyeicosatetraenoic acid is a preferential peroxisome proliferator-activated receptor beta/delta agonist. Mol. Pharmacol. 77, 171-184.
166. Negishi, M., Pedersen, L. G., Petrotchenko, E., Shevtsov, S., Gorokhov, A., Kakuta, Y., and Pedersen, L. C. (2001). Structure and function of sulfotransferases. Arch. Biochem. Biophys. 390, 149-157.
167. Negishi, T., Kato, Y., Ooneda, O., Mimura, J., Takada, T., Mochizuki, H., Yamamoto, M., Fujii-Kuriyama, Y., and Furusako, S. (2005). Effects of aryl hydrocarbon receptor signaling on the modulation of TH1/TH2 balance. J. Immunol. 175, 7348-7356.
168. Nelson, D. R. (2009). The cytochrome P450 homepage. Hum. Genomics 4, 59-65.
169. Okamoto, H., Katagiri, Y., Kiire, A., Momohara, S., and Kamatani, N. (2008). Serum amyloid A activates nuclear factor-kappaB in rheumatoid synovial fibroblasts through binding to receptor of advanced glycation end-products. J. Rheumatol. 35, 752-756.
170. Olsavsky, K. M., Page, J. L., Johnson, M. C., Zarbl, H., Strom, S. C., and Omiecinski, C. J. (2007). Gene expression profiling and differentiation assessment in primary human hepatocyte cultures, established hepatoma cell lines, and human liver tissues. Toxicol. Appl. Pharmacol. 222, 42-56.
171. Omura, T., and Sato, R. (1962). A new cytochrome in liver microsomes. J. Biol. Chem. 237, 1375-1376.
172. Palkar, P. S., Borland, M. G., Naruhn, S., Ferry, C. H., Lee, C., Sk, U. H., Sharma, A. K., Amin, S., Murray, I. A., Anderson, C. R., et al. (2010). Cellular and pharmacological selectivity of the PPAR{beta}/{delta} antagonist GSK3787. Mol. Pharmacol. 276, 79-84.
173. Patel, R. D., Murray, I. A., Flaveny, C. A., Kusnadi, A., and Perdew, G. H. (2009). Ah receptor represses acute-phase response gene expression without binding to its cognate response element. Lab. Invest. 89, 695-707.
174. Peck, A., and Mellins, E. D. (2009). Breaking old paradigms: Th17 cells in autoimmune arthritis. Clin. Immunol. 132, 295-304.
175. Pelclova, D., Urban, P., Preiss, J., Lukas, E., Fenclova, Z., Navratil, T., Dubska, Z., and Senholdova, Z. (2006). Adverse health effects in humans exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Rev. Environ. Health 21, 119-138.
176. Peraza, M. A., Burdick, A. D., Marin, H. E., Gonzalez, F. J., and Peters, J. M. (2006). The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR). Toxicol. Sci. 90, 269-295.
177. Peters, J. M., Cattley, R. C., and Gonzalez, F. J. (1997). Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643. Carcinogenesis 18, 2029-2033.
178. Peters, J. M., and Gonzalez, F. J. (2009). Sorting out the functional role(s) of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) in cell proliferation and cancer. Biochim. Biophys. Acta 1796, 230-241.
179. Peters, J. M., Hollingshead, H. E., and Gonzalez, F. J. (2008). Role of peroxisome-proliferator-activated receptor beta/delta (PPARbeta/delta) in gastrointestinal tract function and disease. Clin. Sci. (Lond) 115, 107-127.
180. Qatanani, M., Zhang, J., and Moore, D. D. (2005). Role of the constitutive androstane receptor in xenobiotic-induced thyroid hormone metabolism. Endocrinology 146, 995-1002.
181. Ramadoss, P., and Perdew, G. H. (2004). Use of 2-azido-3-[125I]iodo-7, 8-dibromodibenzo-p-dioxin as a probe to determine the relative ligand affinity of human versus mouse aryl hydrocarbon receptor in cultured cells. Mol. Pharmacol. 66, 129-136.
182. Ramsden, R., Beck, N. B., Sommer, K. M., and Omiecinski, C. J. (1999). Phenobarbital responsiveness conferred by the 5'-flanking region of the rat CYP2B2 gene in transgenic mice. Gene 228, 169-179.
183. Reddy, J. K., and Krishnakantha, T. P. (1975). Hepatic peroxisome proliferation: induction by two novel compounds structurally unrelated to clofibrate. Science 190, 787-789.
184. Reddy, J. K., and Lalwani, N. D. (1983). Carcinogenesis by hepatic peroxisome proliferators: evaluation of the risk of hypolipidemic drugs and industrial plasticizers to humans. Crit. Rev. Toxicol. 12, 1-58.
185. Reddy, J. K., Rao, S., and Moody, D. E. (1976). Hepatocellular carcinomas in acatalasemic mice treated with nafenopin, a hypolipidemic peroxisome proliferator. Cancer Res. 36, 1211-1217.
186. Remmer, H. (1959). Die bescheunigung der Evipanoxydation und der Dimethylierung von Methylaminoantipyrin durch Barbituate. Arch. Exp. Pathol. Pharmacol. 237, 296.
187. Reschly, E. J., and Krasowski, M. D. (2006). Evolution and function of the NR1I nuclear hormone receptor subfamily (VDR, PXR, and CAR) with respect to metabolism of xenobiotics and endogenous compounds. Curr. Drug Metab. 7, 349-365.
188. Reyes-Hernandez, O. D., Mejia-Garcia, A., Sanchez-Ocampo, E. M., Cabanas-Cortes, M. A., Ramirez, P., Chavez-Gonzalez, L., Gonzalez, F. J., and Elizondo, G. (2010). Ube2l3 gene expression is modulated by activation of the aryl hydrocarbon receptor: implications for p53 ubiquitination. Biochem. Pharmacol. 80, 932-940.
189. Ross, J., Plummer, S. M., Rode, A., Scheer, N., Bower, C. C., Vogel, O., Henderson, C. J., Wolf, C. R., and Elcombe, C. R. (2010). Human constitutive androstane receptor (CAR) and pregnane X receptor (PXR) support the hypertrophic but not the hyperplastic response to the murine nongenotoxic hepatocarcinogens phenobarbital and chlordane in vivo. Toxicol. Sci. 116, 452-466.
190. Savolainen, H. A., and Isomaki, H. A. (1993). Decrease in the number of deaths from secondary amyloidosis in patients with juvenile rheumatoid arthritis. J. Rheumatol. 20, 1201-1203.
191. Scheer, N., Ross, J., Rode, A., Zevnik, B., Niehaves, S., Faust, N., and Wolf, C. R. (2008). A novel panel of mouse models to evaluate the role of human pregnane X receptor and constitutive androstane receptor in drug response. J. Clin. Invest. 118, 3228-3239.
192. Schopfer, F. J., Lin, Y., Baker, P. R., Cui, T., Garcia-Barrio, M., Zhang, J., Chen, K., Chen, Y. E., and Freeman, B. A. (2005). Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor gamma ligand. Proc. Natl. Acad. Sci. U.S.A. 102, 2340-2345.
193. Schroeder, J. C., DiNatale, B. C., Murray, I. A., Flaveny, C. A., Liu, Q., Laurenzana, E. M., Lin, J. M., Strom, S. C., Omiecinski, C. J., and Amin, S. (2010). The uremic toxin 3-indoxyl sulfate is a potent endogenous agonist for the human aryl hydrocarbon receptor. Biochemistry 49, 393-400.
194. Scotto, K. W. (2003). Transcriptional regulation of ABC drug transporters. Oncogene 22, 7496-7511.
195. Semple, R. K., Chatterjee, V. K., and O'Rahilly, S. (2006). PPAR gamma and human metabolic disease. J. Clin. Invest. 116, 581-589.
196. Shah, Y. M., Morimura, K., Yang, Q., Tanabe, T., Takagi, M., and Gonzalez, F. J. (2007). Peroxisome proliferator-activated receptor alpha regulates a microRNA-mediated signaling cascade responsible for hepato-cellular proliferation. Mol. Cell. Biol. 27, 4238-4247.
197. Shan, W., Nicol, C. J., Ito, S., Bility, M. T., Kennett, M. J., Ward, J. M., Gonzalez, F. J., and Peters, J. M. (2008a). Peroxisome proliferator-activated receptor-beta/delta protects against chemically induced liver toxicity in mice. Hepatology 47, 225-235.
198. Shan, W., Palkar, P. S., Murray, I. A., McDevitt, E. I., Kennett, M. J., Kang, B. H., Isom, H. C., Perdew, G. H., Gonzalez, F. J., and Peters, J. M. (2008b). Ligand activation of peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) attenuates carbon tetrachloride hepatotoxicity by downregulating proinflammatory gene expression. Toxicol. Sci. 105, 418-428.
199. Shearer, B. G., Wiethe, R. W., Ashe, A., Billin, A. N., Way, J. M., Stanley, T. B., Wagner, C. D., Xu, R. X., Leesnitzer, L. M., and Merrihew, R. V. (2010). Identification and characterization of 4-chloro-N-(2-{[5-trifluoromethyl)-2-pyridyl]sulfonyl}ethyl)benzamide (GSK3787), a selective and irreversible peroxisome proliferator-activated receptor delta (PPARdelta) antagonist. J. Med. Chem. 53, 1857-1861.
200. Sim, E., Lack, N., Wang, C. J., Long, H., Westwood, I., Fullam, E., and Kawamura, A. (2008). Arylamine N-acetyltransferases: structural and functional implications of polymorphisms. Toxicology 254, 170-183.
201. Sladek, N. E., and Mannering, G. J. (1966). Evidence for a new P-450 hemoprotein in hepatic microsomes from methylcholanthrene treated rats. Biochem. Biophys. Res. Commun. 22, 668-674.
202. Smith, R. L., and Williams, R. T. (1970). History of the discovery of the conjugation mechanisms. In Metabolic Conjugation and Metabolic Hydrolysis (W. H. Fishman, Ed.), pp. 1-19. Academic Press, New York, NY.
203. Stedman, C. A., Liddle, C., Coulter, S. A., Sonoda, J., Alvarez, J. G., Moore, D. D., Evans, R. M., and Downes, M. (2005). Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury. Proc. Natl. Acad. Sci. U.S.A. 102, 2063-2068.
204. Sueyoshi, T., and Negishi, M. (2001). Phenobarbital response elements of cytochrome p450 genes and nuclear receptors. Annu. Rev. Pharmacol. Toxicol. 41, 123-143.
205. Suino, K., Peng, L., Reynolds, R., Li, Y., Cha, J. Y., Repa, J. J., Kliewer, S. A., and Xu, H. E. (2004). The nuclear xenobiotic receptor CAR: structural determinants of constitutive activation and heterodimerization. Mol. Cell 16, 893-905.
206. Sundvold, H., and Lien, S. (2001). Identification of a novel peroxisome proliferator-activated receptor (PPAR) gamma promoter in man and transactivation by the nuclear receptor RORalpha1. Biochem. Biophys. Res. Commun. 287, 383-390.
207. Swales, K., and Negishi, M. (2004). CAR, driving into the future. Mol. Endocrinol. 18, 1589-1598.
208. Sznaidman, M. L., Haffner, C. D., Maloney, P. R., Fivush, A., Chao, E., Goreham, D., Sierra, M. L., LeGrumelec, C., Xu, H. E., and Montana, V. G. (2003). Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta)-synthesis and biological activity. Bioorg. Med. Chem. Lett. 13, 1517-1521.
209. Tanaka, T., Yamamoto, J., Iwasaki, S., Asaba, H., Hamura, H., Ikeda, Y., Watanabe, M., Magoori, K., Ioka, R. X., and Tachibana, K. (2003). Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc. Natl. Acad. Sci. U.S.A. 100, 15924-15929.
210. Thomas, P. E., Lu, A. Y., Ryan, D., West, S. B., Kawalek, J., and Levin, W. (1976). Immunochemical evidence for six forms of rat liver cytochrome P450 obtained using antibodies against purified rat liver cytochromes P450 and P448. Mol. Pharmacol. 12, 746-758.
211. Tian, Y., Ke, S., Denison, M. S., Rabson, A. B., and Gallo, M. A. (1999). Ah receptor and NF-kappaB interactions, a potential mechanism for dioxin toxicity. J. Biol. Chem. 274, 510-515.
212. Timsit, Y. E., and Negishi, M. (2007). CAR and PXR: the xenobiotic-sensing receptors. Steroids 72, 231-246.
213. Tontonoz, P., Hu, E., Graves, R. A., Budavari, A. I., and Spiegelman, B. M. (1994a). mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. 8, 1224-1234.
214. Tontonoz, P., Hu, E., and Spiegelman, B. M. (1994b). Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 79, 1147-1156.
215. Trottier, E., Belzil, A., Stoltz, C., and Anderson, A. (1995). Localization of a phenobarbital-responsive element (PBRE) in the 5'-flanking region of the rat CYP2B2 gene. Gene 158, 263-268.
216. Tugwood, J. D., Issemann, I., Anderson, R. G., Bundell, K. R., McPheat, W. L., and Green, S. (1992). The mouse peroxisome proliferator activated receptor recognizes a response element in the 5' flanking sequence of the rat acyl CoA oxidase gene. EMBO J. 11, 433-439.
217. Tzameli, I., Pissios, P., Schuetz, E. G., and Moore, D. D. (2000). The xenobiotic compound 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene is an agonist ligand for the nuclear receptor CAR. Mol. Cell. Biol. 20, 2951-2958.
218. Ueda, A., Hamadeh, H. K., Webb, H. K., Yamamoto, Y., Sueyoshi, T., Afshari, C. A., Lehmann, J. M., and Negishi, M. (2002). Diverse roles of the nuclear orphan receptor CAR in regulating hepatic genes in response to phenobarbital. Mol. Pharmacol. 61, 1-6.
219. Urquhart, B. L., Tirona, R. G., and Kim, R. B. (2007). Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs. J. Clin. Pharmacol. 47, 566-578.
220. Vanden Heuvel, J. P. (2004). Diet, fatty acids, and regulation of genes important for heart disease. Curr. Atheroscler. Rep. 6, 432-440.
221. Vazquez, J. J., and Marigil, M. A. (1989). Liver-cell adenoma in an epileptic man on barbiturates. Histol. Histopathol. 4, 301-303.
222. Veldhoen, M., Hirota, K., Christensen, J., O'Garra, A., and Stockinger, B. (2009). Natural agonists for aryl hydrocarbon receptor in culture medium are essential for optimal differentiation of Th17 T cells. J. Exp. Med. 206, 43-49.
223. Veldhoen, M., Hirota, K., Westendorf,A.M., Buer, J., Dumoutier, L., Renauld,J. C., and Stockinger, B. (2008). The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature 453, 106-109.
224. Villano, C. M., Murphy, K. A., Akintobi, A., and White, L. A. (2006). 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) induces matrix metallo-proteinase (MMP) expression and invasion in A2058 melanoma cells. Toxicol. Appl. Pharmacol. 210, 212-224.
225. Wada, T., Gao, J., and Xie, W. (2009). PXR and CAR in energy metabolism. Trends Endocrinol. Metab. 20, 273-279.
226. Waller, C. L., and McKinney, J. D. (1995). Three-dimensional quantitative structure-activity relationships of dioxins and dioxin-like compounds: model validation and Ah receptor characterization. Chem. Res. Toxicol. 8, 847-858.
227. Wan, Y., Chong, L. W., and Evans, R. M. (2007). PPAR-gamma regulates osteoclastogenesis in mice. Nat. Med. 13, 1496-1503.
228. Wang, D., Wang, H., Guo, Y., Ning, W., Katkuri, S., Wahli, W., Desvergne, B., Dey, S. K., and DuBois, R. N. (2006). Crosstalk between peroxisome proliferator-activated receptor delta and VEGF stimulates cancer progression. Proc. Natl. Acad. Sci. U.S.A. 103, 19069-19074.
229. Wang, H., Faucette, S., Moore, R., Sueyoshi, T., Negishi, M., and LeCluyse, E. (2004). Human constitutive androstane receptor mediates induction of CYP2B6 gene expression by phenytoin. J. Biol. Chem. 279, 29295-29301.
230. Watkins, P. B. (2005). Idiosyncratic liver injury: challenges and approaches. Toxicol. Pathol. 33, 1-5.
231. Watkins, P. B., and Whitcomb, R. W. (1998). Hepatic dysfunction associated with troglitazone. N. Engl. J. Med. 338, 916-917.
232. Watkins, R. E., Maglich, J. M., Moore, L. B., Wisely, G. B., Noble, S. M., Davis-Searles, P. R., Lambert, M. H., Kliewer, S. A., and Redinbo, M. R. (2003). 2.1 A crystal structure of human PXR in complex with the St. John's wort compound hyperforin. Biochemistry 42, 1430-1438.
233. Watkins, R. E., Noble, S. M., and Redinbo, M. R. (2002). Structural insights into the promiscuity and function of the human pregnane X receptor. Curr. Opin. Drug Discov. Dev. 5, 150-158.
234. Welch, J. S., Ricote, M., Akiyama, T. E., Gonzalez, F. J., and Glass, C. K. (2003). PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages. Proc. Natl. Acad. Sci. U.S.A. 100, 6712-6717.
235. Wilce, M. C., and Parker, M. W. (1994). Structure and function of glutathione S-transferases. Biochim. Biophys. Acta 1205, 1-18.
236. Wilkins, J., Gallimore, J. R., Tennent, G. A., Hawkins, P. N., Limburg, P. C., van Rijswijk, M. H., Moore, E. G., and Pepys, M. B. (1994). Rapid automated enzyme immunoassay of serum amyloid A. Clin. Chem. 40(Pt 1), 1284-1290.
237. Williams, R. T. (1959). In Detoxication Mechanisms: The Metabolism and Detoxication of Drugs, Toxic Substances and Other Organic Compounds. Wiley, New York, NY.
238. Woods, C. G., Heuvel, J. P., and Rusyn, I. (2007). Genomic profiling in nuclear receptor-mediated toxicity. Toxicol. Pathol. 35, 474-494.
239. Xu, C., Li, C. Y., and Kong, A. N. (2005a). Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch. Pharm. Res. 28, 249-268.
240. Xu, R. X., Lambert, M. H., Wisely, B. B., Warren, E. N., Weinert, E. E., Waitt, G. M., Williams, J. D., Collins, J. L., Moore, L. B., Willson, T. M., et al. (2004). A structural basis for constitutive activity in the human CAR/RXRalpha heterodimer. Mol. Cell 16, 919-928.
241. Xu, Y., Gen, M., Lu, L., Fox, J., Weiss, S. O., Brown, R. D., Perlov, D., Ahmad, H., Zhu, P., Greyson, C., et al. (2005b). PPAR-gamma activation fails to provide myocardial protection in ischemia and reperfusion in pigs. Am. J. Physiol. Heart Circ. Physiol. 288, H1314-H1323.
242. Yamamoto, Y., Moore, R., Flavell, R. A., Lu, B., and Negishi, M. (2010). Nuclear receptor CAR represses TNFalpha-induced cell death by interacting with the anti-apoptotic GADD45B. PLoS ONE 5, e10121.
243. Yamamoto, Y., Moore, R., Goldsworthy, T. L., Negishi, M., and Maronpot, R. R. (2004). The orphan nuclear receptor constitutive active/androstane receptor is essential for liver tumor promotion by phenobarbital in mice. Cancer Res. 64, 7197-7200.
244. Yao, R., Yasuoka, A., Kamei, A., Kitagawa, Y., Tateishi, N., Tsuruoka, N., Kiso, Y., Sueyoshi, T., Negishi, M., Misaka, T., et al. (2010). Dietary flavonoids activate the constitutive androstane receptor (CAR). J. Agric. Food Chem. 58, 2168-2173.
245. Zacharewski, T., Harris, M., Biegel, L., Morrison, V., Merchant, M., and Safe, S. (1992). 6-Methyl-1,3,8-trichlorodibenzofuran (MCDF) as an antiestrogen in human and rodent cancer cell lines: evidence for the role of the Ah receptor. Toxicol. Appl. Pharmacol. 113, 311-318.
246. Zhai, Y., Wada, T., Zhang, B., Khadem, S., Ren, S., Kuruba, R., Li, S., and Xie, W. (2010). A functional crosstalk between LXR{alpha} and CAR links lipogenesis and xenobiotic responses. Mol. Pharmacol. 78, 666-674.
247. Zhang, J., Huang, W., Chua, S. S., Wei, P., and Moore, D. D. (2002). Modulation of acetaminophen-induced hepatotoxicity by the xenobiotic receptor CAR. Science 298, 422-424.
248. Zhang, J., Huang, W., Qatanani, M., Evans, R. M., and Moore, D. D. (2004). The constitutive androstane receptor and pregnane X receptor function coordinately to prevent bile acid-induced hepatotoxicity. J. Biol. Chem. 279, 49517-49522.
249. Zhu, Y., Alvares, K., Huang, Q., Rao, M. S., and Reddy, J. K. (1993). Cloning of a new member of the peroxisome proliferator-activated receptor gene family from mouse liver. J. Biol. Chem. 268, 26817-26820.
250. Zhu, Y., Qi, C., Korenberg, J. R., Chen, X. N., Noya, D., Rao, M. S., and Reddy, J. K. (1995). Structural organization of mouse peroxisome proliferator-activated receptor gamma (mPPAR gamma) gene: alternative promoter use and different splicing yield two mPPAR gamma isoforms. Proc. Natl. Acad. Sci. U.S.A. 92, 7921-7925.